The targeting of nanocarriers not only enhances the bioavailability of drugs at the lesion site but also effectively avoids acute and chronic metabolic toxicity (such as hyperglycemia) caused by extensive inhibition of the PI3K pathway in traditional treatments by limiting system exposure. The gene discussed is PIK3CD; the disease is Hyperglycemia.